Relacorilant and Surgery Improve Hemostatic Markers in Cushing's Syndrome
• A study shows that hypercoagulopathy, a complication in Cushing's Syndrome (CS), improves with both relacorilant treatment and surgery.
• Relacorilant, a selective glucocorticoid receptor modulator (SGRM), demonstrated improvements in coagulation markers after 3-4 months of treatment.
• Surgical intervention also led to improvements in coagulation markers within an average of 6 months post-operation in CS patients.
• The study suggests relacorilant may offer a beneficial treatment option for CS patients, particularly those at high risk of VTE or not suitable for surgery.
© Copyright 2025. All Rights Reserved by MedPath